SPOTLIGHT -
EP. 1: The Current Understanding of Biomarkers in Melanoma
EP. 2: Case I: Newly Diagnosed BRAF Wild Type Advanced Melanoma
EP. 3: Melanoma: Helping Patients Understand Immunotherapy
EP. 4: Immunotherapy in Melanoma: Managing Toxicities
EP. 5: Case 2: Frontline Decisions in Stage IV BRAF-mutant Melanoma
EP. 6: Achieving Durable Responses in Advanced Melanoma
EP. 7: Patient Selection in Melanoma: Immunotherapy vs Targeted Therapy
EP. 8: Sequencing Decisions and Multidisciplinary Care in Metastatic Melanoma
EP. 9: Melanoma: Nuances of BRAF/MEK Combinations in the Front line
EP. 10: Case 3: Post-Surgical Recurrent Melanoma
EP. 11: Adjuvant Therapy Options in Advanced Melanoma
EP. 12: Alternative Adjuvant Approaches in Stage III Melanoma
EP. 13: Neoadjuvant Trials in High-risk Melanoma
EP. 14: T-VEC Data in the Neoadjuvant Setting in Melanoma
EP. 15: Remaining Research Questions in Advanced Melanoma
EP. 16: The Future Management of Melanoma
Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors
Navigating Systemic Therapy for RCC: Balancing Risk Status and Response
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC
Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making
